Philippines - English - FDA (Food And Drug Administration)

zydus healthcare philippines inc.; distributor: zydus healthcare philippines inc. - atorvastatin (as calcium) - film-coated tablet - 20 mg

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 7.5 mg - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see clinical studies  (14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see clinical studies  (14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients who weigh ≥60 kg [see dosage and administration (2.4) and clinical studies (14.2) ]. meloxicam is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7,5.8) ] - in the setting of coronary ar

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. ketorolac tromethamine tablets are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with iv or im dosing of ketorolac tromethamine and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings , precautions , dosage and administration , and adverse reactions ). patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine tablet therapy is not to exceed 5 days. (see also boxed warning) ketorolac tromethamine tablets are contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine. ketorolac tromethamine tablets are contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. ketorolac tromethamine tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions and precautions, preexisting asthma ). ketorolac tromethamine tablets are contraindicated as prophylactic analgesic before any major surgery. ketorolac tromethamine tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ). ketorolac tromethamine tablets are contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion (see warnings for correction of volume depletion). ketorolac tromethamine tablets are contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage. ketorolac tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see warnings and precautions ). ketorolac tromethamine tablets are contraindicated in patients currently receiving aspirin or nsaids because of the cumulative risks of inducing serious nsaid-related adverse events. the concomitant use of ketorolac tromethamine and probenecid is contraindicated. the concomitant use of ketorolac tromethamine and pentoxifylline is contraindicated.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains lamotrigine 50,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains alendronate sodium equivalent to alendronic acid 70,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - capsules - see ingredients - each capsule contains tamsulosin hydrochloride 0,4 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains risperidone 1,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains risperidone 2,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains risperidone 3,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains risperidone 4,0 mg